X

Regeneron Pharmaceuticals Inc (REGN) Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

Newsdesk: